This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davidson, B. Articles by Nesland, J. M. Search for Related Content PubMed PubMed Citation Articles by Davidson, B. Articles by Nesland, J. M. Related Collections Commentary

Ets-1 Messenger RNA Expression Is a Novel Marker of Poor Survival in Ovarian Carcinoma

Department of Pathology, The Norwegian Radium Hospital, Montebello N-0310 Oslo, Norway, affiliated with the University of Oslo, Oslo N-0216 Norway [B. D., A. B., J. M. N.]; Department of Pharmacology, Faculty of Medicine and David R. Bloom Center for Pharmacy, Hebrew University, Jerusalem 91120, Israel [R. R.]; Department of Pathology [I. G., J. K.] and Division of Gynecologic Oncology [W. H. G., G. B-B.], Sheba Medical Center, Tel-Hashomer 52621, Israel, affiliated with Sackler School of Medicine, Tel-Aviv University; and Department of Oral Biology, University of Oslo, Oslo, Norway [M. B.]

Ets-1 proto-oncogene is a transcription factor involved in several cellular functions, including the activation of several proteases participating in tumor invasion and metastasis. The objective of this study was to analyze the possible correlation between Ets-1 mRNA expression and survival in advanced-stage ovarian carcinomas, studying two patient groups with extremely different disease outcome. Sections from 66 primary ovarian carcinomas and metastatic lesions from 41 patients diagnosed with advanced-stage ovarian carcinoma (International Federation of Gynecologists and Obstetricians stages III and IV) were evaluated for expression of Ets-1 using mRNA in situ hybridization. Patients were divided into long-term (n = 17) and short-term (n = 24) survivors. The mean values for disease-free survival and overall survival were 116 and 133 months for long-term survivors, as compared to 3 and 21 months for short-term survivors, respectively. Expression of Ets-1 mRNA was detected in carcinoma cells and stromal cells in 28 of 66 (42%) and 22 of 66 (33%) lesions, respectively. Ets-1 expression showed an association with mRNA expression of vascular endothelial growth factor (P = 0.001 for carcinoma cells; P = 0.004 for stromal cells), basic fibroblast growth factor (P = 0.049 for carcinoma cells), and membrane type-1 matrix metalloproteinase (P = 0.045), which were previously studied in this patient cohort. Ets-1 mRNA was detected more often in both carcinoma and stromal cells in tumors of short-term survivors (P = 0.038 for carcinoma cells). In univariate survival analysis for all cases, Ets-1 expression in both tumor (P = 0.018) and stroma (P = 0.026) correlated with poor survival. These findings were reproduced in an analysis of primary tumors alone (P = 0.039 for tumor cells; P < 0.001 for stromal cells). Ets-1 mRNA expression in stromal cells retained its predictive power in a multivariate survival analysis in which all molecules studied previously in this patient cohort were included (P = 0.007). To our knowledge, this is the first evidence associating Ets-1 mRNA expression and poor survival in human epithelial malignancy. Ets-1 is thus a novel prognostic marker in advanced-stage ovarian carcinoma. The association between Ets-1 mRNA expression and the expression of membrane type-1 matrix metalloproteinase and angiogenic genes, first documented here in a study of patient material, points to the central role of this transcription factor in tumor progression in ovarian carcinoma.

Commentary

The Diverse Role of the ETS Family of Transcription Factors in Cancer: Commentary re: B. Davidson, Ets-1 Messenger RNA Expression Is a Novel Marker of Poor Survival in Ovarian Carcinoma. Clin. Cancer Res., 7: 551–557, 2001.

D. Gary Gilliland
Clin. Cancer Res. 2001 7: 451-453. [Full Text] [PDF]

This article has been cited by other articles:

				T. Sato and K. Furukawa Sequential Action of Ets-1 and Sp1 in the Activation of the Human beta-1,4-Galactosyltransferase V Gene Involved in Abnormal Glycosylation Characteristic of Cancer Cells J. Biol. Chem., September 21, 2007; 282(38): 27702 - 27712. [Abstract] [Full Text] [PDF]

				K. D. Cowden Dahl, R. Zeineldin, and L. G. Hudson PEA3 Is Necessary for Optimal Epidermal Growth Factor Receptor-Stimulated Matrix Metalloproteinase Expression and Invasion of Ovarian Tumor Cells Mol. Cancer Res., May 1, 2007; 5(5): 413 - 421. [Abstract] [Full Text] [PDF]

				B. Davidson, S. Konstantinovsky, S. Nielsen, H. P. Dong, A. Berner, M. Vyberg, and R. Reich Altered Expression of Metastasis-Associated and Regulatory Molecules in Effusions from Breast Cancer Patients: A Novel Model for Tumor Progression Clin. Cancer Res., November 1, 2004; 10(21): 7335 - 7346. [Abstract] [Full Text] [PDF]

				H. Ito, M. Duxbury, E. Benoit, T. E. Clancy, M. J. Zinner, S. W. Ashley, and E. E. Whang Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2 Cancer Res., October 15, 2004; 64(20): 7439 - 7446. [Abstract] [Full Text] [PDF]

				L. A. Wilson, H. Yamamoto, and G. Singh Role of the transcription factor Ets-1 in cisplatin resistance Mol. Cancer Ther., July 1, 2004; 3(7): 823 - 832. [Abstract] [Full Text] [PDF]

				B. Davidson, I. Goldberg, W. H. Gotlieb, J. Kopolovic, G. Ben-Baruch, and R. Reich PEA3 Is the Second Ets Family Transcription Factor Involved in Tumor Progression in Ovarian Carcinoma Clin. Cancer Res., April 1, 2003; 9(4): 1412 - 1419. [Abstract] [Full Text] [PDF]

				I. Goldberg, B. Davidson, R. Reich, W. H. Gotlieb, G. Ben-Baruch, M. Bryne, A. Berner, J. M. Nesland, and J. Kopolovic {alpha}v Integrin Expression Is a Novel Marker of Poor Prognosis in Advanced-stage Ovarian Carcinoma Clin. Cancer Res., December 1, 2001; 7(12): 4073 - 4079. [Abstract] [Full Text] [PDF]